General Information of Drug (ID: DMFAOKP)

Drug Name
Fenoldopam
Synonyms
Carlacor; Fenoldopamum; Fenodopam mesylate; Fenoldopamum [Latin]; SKF 82526; Carlacor (TN); Corlopam (TN); Fenoldopam (INN);Fenoldopam [INN:BAN]; SKF 82526-J; SKF-82526J; SK&F-82526; 6-chloro-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 305.75
Logarithm of the Partition Coefficient (xlogp) 2.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 41.5 mL/min/kg [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 minutes [2]
Metabolism
The drug is metabolized via the conjugation, without participation of cytochrome P-450 enzymes []
Unbound Fraction
The unbound fraction of drug in plasma is 0.12% [2]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.5 L/kg [2]
Chemical Identifiers
Formula
C16H16ClNO3
IUPAC Name
9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol
Canonical SMILES
C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O
InChI
InChI=1S/C16H16ClNO3/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21/h1-4,7,13,18-21H,5-6,8H2
InChIKey
TVURRHSHRRELCG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3341
ChEBI ID
CHEBI:5002
CAS Number
67227-56-9
DrugBank ID
DB00800
TTD ID
D0R6BI
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hypertension
ICD Disease Classification BA00-BA04
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D1 receptor (D1R) DTT DRD1 8.99E-01 -0.06 -0.3
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fenoldopam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Fenoldopam and Dronedarone. Angina pectoris [BA40] [4]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Fenoldopam and Cariprazine. Bipolar disorder [6A60] [5]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Fenoldopam and Selegiline. Depression [6A70-6A7Z] [6]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Fenoldopam and Isocarboxazid. Depression [6A70-6A7Z] [6]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Fenoldopam and OPC-34712. Depression [6A70-6A7Z] [5]
Procarbazine DMIK367 Moderate Additive hypotensive effects by the combination of Fenoldopam and Procarbazine. Hodgkin lymphoma [2B30] [6]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Fenoldopam and ITI-007. Insomnia [7A00-7A0Z] [5]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Fenoldopam and Arsenic trioxide. Mature B-cell lymphoma [2A85] [7]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Fenoldopam and Ozanimod. Multiple sclerosis [8A40] [6]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Fenoldopam and Promethazine. Nausea/vomiting [MD90] [5]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Fenoldopam and Levomethadyl Acetate. Opioid use disorder [6C43] [8]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Fenoldopam and Safinamide. Parkinsonism [8A00] [6]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Fenoldopam and Rasagiline. Parkinsonism [8A00] [6]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Fenoldopam and Levomepromazine. Psychotic disorder [6A20-6A25] [5]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Fenoldopam and Quetiapine. Schizophrenia [6A20] [5]
Mesoridazine DM2ZGAN Moderate Additive hypotensive effects by the combination of Fenoldopam and Mesoridazine. Schizophrenia [6A20] [5]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Fenoldopam and Aripiprazole. Schizophrenia [6A20] [5]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Fenoldopam and Iloperidone. Schizophrenia [6A20] [5]
Paliperidone DM7NPJS Moderate Additive hypotensive effects by the combination of Fenoldopam and Paliperidone. Schizophrenia [6A20] [5]
Perphenazine DMA4MRX Moderate Additive hypotensive effects by the combination of Fenoldopam and Perphenazine. Schizophrenia [6A20] [5]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Fenoldopam and Molindone. Schizophrenia [6A20] [5]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Fenoldopam and Thiothixene. Schizophrenia [6A20] [5]
Trifluoperazine DMKBYWI Moderate Additive hypotensive effects by the combination of Fenoldopam and Trifluoperazine. Schizophrenia [6A20] [5]
Amisulpride DMSJVAM Moderate Additive hypotensive effects by the combination of Fenoldopam and Amisulpride. Schizophrenia [6A20] [5]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Fenoldopam and Asenapine. Schizophrenia [6A20] [5]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Fenoldopam and Pimozide. Schizophrenia [6A20] [9]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Fenoldopam and Methdilazine. Vasomotor/allergic rhinitis [CA08] [5]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Fenoldopam and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [10]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Fenoldopam and Amiodarone. Ventricular tachyarrhythmia [BC71] [11]
⏷ Show the Full List of 29 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 985).
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9.
4 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
5 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
6 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
7 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
8 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
9 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
10 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
11 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]